Join us   Log in  


Pages: 990-995
Print Article   Download XML  Download PDF

Primary biliary cholangitis: Predictors of Poor Response to Ursodeoxycholic Acid after 1 Year of Treatment in Moroccan Patients

Author: Hakima Abid, Inssaf Akoch, Maria Lahlali, Nada Lahmidani, Mounia Elyousfi, Dafrallah Benajah, Mohamed El Abkari, Adil Ibrahimi

Category: JMSR Gastroenterology


Introduction: Primary biliary cholangitis (PBC), the new dominance of primary biliary cirrhosis, is a cholestatic disease of autoimmune etiology and represents the leading cause of intra-hepatic cholestasis. Treatment is mainly based on ursodeoxycholic acid. The biological response to treatment is the main predictor of survival without liver transplantation. The Globe-score has been recently validated as the main prognostic factor. Materials and methods: This is a retrospective study carried out in our department collating all cases of PBC followed in consultation. The aim of our work is to research the predictors of poor response to UDCA. Results: 46 patients were collected. The mean age of the patients was 58.82 years, with a predominance of women (n = 43, 93.5%). 34.78% of patients were in the stage of cirrhosis. Anti-M2 mitochondria antibodies were positive in 44 patients (95.65%). An overlap syndrome was found in 11 patients (23.9%). Treatment was based on UDCA combined with corticosteroid therapy and immunosuppressant for overlap syndrome. A biochemical response at 1 year of treatment according to the Paris II criteria was found in 47.8%. The average value of the globe score was 1.35. A score greater than 0.30 was objectified in 20 cases (43.47%). Nineteen cirrhotic patients (41.30%) had a globe score> 0.30. Factors associated with poor response to therapy were: stage of decompensated cirrhosis, elevated pre-therapy total bilirubin greater than 30 g / l and hypoalbunemia less than 35 g / l. The study of the correlation between Globe score and Paris II showed a strong and significant association with a correlation coefficient estimated at 67%. The Paris II score was significantly correlated with the response to treatment (p = 0.001). Conclusion: In accordance with the data in the literature, the globe-score and Paris II are two similar predictive means for evaluating the response at 1 year of treatment in Moroccan context.

Keywords: Morocco, Predictors of response, Primary biliary cholangitis, Ursodeoxycholic acid

DOI: 10.46327/msrjg.1.000000000000202



  1. Boonstra K, Kunst AE, Stadhouders PH, et al. Rising incidence and prevalence of primary biliary cirrhosis: a large population-based study. Liver Int. 2014; 34: e31-8.
  2. Lammers WJ, Hirschfield GM, Corpechot C, Nevens F, Lindor KD, Janssen HL, et al. Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy. Gastroenterology 2015; 149: 1804–1812.
  3. Marco Carbon et al Clinical Application of the GLOBE and United Kingdom-Primary Biliary Cholangitis Risk Scores in a Trial Cohort of Patients With Primary Biliary Cholangitis. Hepatology Communications, 2018 ; II (6).
  4. Corpechot C. La cirrhose biliaire primitive. Post’U 2013; 147-154.
  5. Invernizzi P, Selmi C, Ranftler C, Podda M, Wesierska-Gadek J. Antinuclear antibodies in primary biliary cirrhosis. Semin Liver Dis. 2005; 25 (3): 298– 310.
  6. Witt-Sullivan H, Heathcote J, Cauch K, Blendis L, Ghent C, Katz A, et al. The demography of primary biliary cirrhosis in Ontario, Canada. Hepatology. 1990; 12 (1) :98– 105.
  7. Kapelman B, Schaffner F. The natural history of primary biliary cirrhosis. Semin Liver Dis. 1981; I(4): 273–81.
  8. Prince M, Chetwyn A, Craig W, Metcalf J and James O. Asymptomatic primary biliary cirrhosis: clinical feature, prognosis and symptom progression in a large population based cohort. Gut 2004; 53: 865-70.
  9. Fox RA, Scheuer PJ, Scherlock S et al. Asymptomatic PBC. Gut 1973; 14: 444-7.
  10. Springer J, Cauch-Dudek K, Orourke K, Wanless IR et Heathcote J. Asymptomatic primary biliary cirrhosis: A study of naturel history and prognosis. Am J Gasteroenterol 1999; 94: 47-53.
  11. Marschall H-U, Henriksson I, Lindberg S, So? derdahl F, Thuresson M, Wahlin S, et al. Incidence, prevalence, and outcome of primary biliary cholangitis in a nationwide Swedish population-based cohort. Sci Rep [Internet]. Available from: 809/
  12. N. Maamouri, S. Chouaib, L. Abbes, H. Ouerghi, F. Ben Hriz, N. Belkahia, et al. La cirrhose biliaire primitive en Tunisie: a? propos de 43 cas. Gastro- ente?rologie B, ho?pital la Rabta, Tunis 2008
  13. Gong Y, Huang Z, Christensen E, Gluud C. Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta- analysis of randomized clinical trials using Bayesian approach as sensitivity analyses. Am J Gastroenterol. 2007; 102 (8): 1799–807.
  14. Corpechot C, Carrat F, Bahr A, Chre?tien Y, Poupon R- E, Poupon R. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology. 2005;128 (2): 297–303.
  15. Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018; hep.30145.
  16. Hirschfield GM, Beuers U, Corpechot C, Invernizzi P, Jones D, Marzioni M, et al. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. Journal of Hepatology. 2017; 67 (1): 145–72.
  17. Lammers WJ, Hirschfield GM, Corpechot C, Nevens F, Lindor KD, Janssen HLA, et al. Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy. Gastroenterology. 2015; 149 (7): 1804-1812.e4.
  18. Carbone M, Sharp SJ, Flack S, Paximadas D, Spiess K, Adgey C, et al. The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis. Hepatology. 2016;63 (3): 930–50
  19. N. Elleuch, B. Hasnaoui, W. Dahman et al. Corrélation entre le score Globe et la réponse à l’acide urso- désoxycholique au cours de la cholangite biliaire primitive. JFHOD 2018 (P001008).